ARTICLE | Company News
arGEN-X sales and marketing update
March 26, 2012 7:00 AM UTC
arGEN-X launched its NHance technology to increase the half life of a therapeutic antibody in humans by two mutations in the Fc region of the antibody. The company plans to apply the technology to its...